Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282934967> ?p ?o ?g. }
- W4282934967 abstract "Abstract Background A previous European Headache Federation (EHF) guideline addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway to prevent migraine. Since then, randomized controlled trials (RCTs) and real-world evidence have expanded the evidence and knowledge for those treatments. Therefore, the EHF panel decided to provide an updated guideline on the use of those treatments. Methods The guideline was developed following the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach. The working group identified relevant questions, performed a systematic review and an analysis of the literature, assessed the quality of the available evidence, and wrote recommendations. Where the GRADE approach was not applicable, expert opinion was provided. Results We found moderate to high quality of evidence to recommend eptinezumab, erenumab, fremanezumab, and galcanezumab in individuals with episodic and chronic migraine. For several important clinical questions, we found not enough evidence to provide evidence-based recommendations and guidance relied on experts’ opinion. Nevertheless, we provided updated suggestions regarding the long-term management of those treatments and their place with respect to the other migraine preventatives. Conclusion Monoclonal antibodies targeting the CGRP pathway are recommended for migraine prevention as they are effective and safe also in the long-term." @default.
- W4282934967 created "2022-06-16" @default.
- W4282934967 creator A5008323754 @default.
- W4282934967 creator A5021943444 @default.
- W4282934967 creator A5023775224 @default.
- W4282934967 creator A5027946799 @default.
- W4282934967 creator A5042161523 @default.
- W4282934967 creator A5042558271 @default.
- W4282934967 creator A5047076935 @default.
- W4282934967 creator A5051082265 @default.
- W4282934967 creator A5052696387 @default.
- W4282934967 creator A5054269152 @default.
- W4282934967 creator A5058013247 @default.
- W4282934967 creator A5066091918 @default.
- W4282934967 creator A5069332428 @default.
- W4282934967 creator A5069942848 @default.
- W4282934967 creator A5072993718 @default.
- W4282934967 creator A5073278152 @default.
- W4282934967 creator A5076167756 @default.
- W4282934967 creator A5078543779 @default.
- W4282934967 date "2022-06-11" @default.
- W4282934967 modified "2023-10-16" @default.
- W4282934967 title "European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update" @default.
- W4282934967 cites W1981680557 @default.
- W4282934967 cites W2001650386 @default.
- W4282934967 cites W2004916007 @default.
- W4282934967 cites W2042882845 @default.
- W4282934967 cites W2066832522 @default.
- W4282934967 cites W2116458765 @default.
- W4282934967 cites W2156098321 @default.
- W4282934967 cites W2157733244 @default.
- W4282934967 cites W2268603990 @default.
- W4282934967 cites W2466122216 @default.
- W4282934967 cites W2549116677 @default.
- W4282934967 cites W2608751463 @default.
- W4282934967 cites W2768357559 @default.
- W4282934967 cites W2770965214 @default.
- W4282934967 cites W2780526171 @default.
- W4282934967 cites W2792811290 @default.
- W4282934967 cites W2803715733 @default.
- W4282934967 cites W2805181790 @default.
- W4282934967 cites W2805822893 @default.
- W4282934967 cites W2805937849 @default.
- W4282934967 cites W2895070640 @default.
- W4282934967 cites W2895460424 @default.
- W4282934967 cites W2898072840 @default.
- W4282934967 cites W2901687990 @default.
- W4282934967 cites W2922174162 @default.
- W4282934967 cites W2936672162 @default.
- W4282934967 cites W2943483025 @default.
- W4282934967 cites W2944253406 @default.
- W4282934967 cites W2955283194 @default.
- W4282934967 cites W2958168162 @default.
- W4282934967 cites W2968435022 @default.
- W4282934967 cites W2980838981 @default.
- W4282934967 cites W2985571327 @default.
- W4282934967 cites W2986364716 @default.
- W4282934967 cites W2991792334 @default.
- W4282934967 cites W2998554460 @default.
- W4282934967 cites W3007053288 @default.
- W4282934967 cites W3012091141 @default.
- W4282934967 cites W3013502865 @default.
- W4282934967 cites W3015052705 @default.
- W4282934967 cites W3030140473 @default.
- W4282934967 cites W3033647323 @default.
- W4282934967 cites W3036323806 @default.
- W4282934967 cites W3037111965 @default.
- W4282934967 cites W3049682323 @default.
- W4282934967 cites W3086189755 @default.
- W4282934967 cites W3087477661 @default.
- W4282934967 cites W3094653551 @default.
- W4282934967 cites W3111843559 @default.
- W4282934967 cites W3118615836 @default.
- W4282934967 cites W3119736242 @default.
- W4282934967 cites W3120635632 @default.
- W4282934967 cites W3120929599 @default.
- W4282934967 cites W3127208638 @default.
- W4282934967 cites W3128382550 @default.
- W4282934967 cites W3136584947 @default.
- W4282934967 cites W3153011597 @default.
- W4282934967 cites W3154099760 @default.
- W4282934967 cites W3155590386 @default.
- W4282934967 cites W3176179751 @default.
- W4282934967 cites W3176461052 @default.
- W4282934967 cites W3176839476 @default.
- W4282934967 cites W3180531776 @default.
- W4282934967 cites W3185467542 @default.
- W4282934967 cites W3188712371 @default.
- W4282934967 cites W3198970595 @default.
- W4282934967 cites W3204111275 @default.
- W4282934967 cites W3207215343 @default.
- W4282934967 cites W3208701883 @default.
- W4282934967 cites W3212380527 @default.
- W4282934967 cites W3213340312 @default.
- W4282934967 cites W4200060556 @default.
- W4282934967 cites W4200153798 @default.
- W4282934967 cites W4205200610 @default.
- W4282934967 cites W4206717983 @default.
- W4282934967 cites W4210569896 @default.
- W4282934967 cites W4210836460 @default.